Verified source report

London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’

Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect. Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS) , when the immune system goes into overdrive and attacks the body, leading to organ damage. Continue reading...

Source-feed image associated with London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’
Source-feed image associated with the linked report: London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’.Credit: The Guardian Source-feed thumbnail displayed with attribution and outbound source link; VINI does not claim ownership or republish the third-party article body. Image source Cached source-feed image shown for continuity with attribution and an outbound source link; VINI does not claim third-party image authorship or republish the third-party article body.

What happened

According to The Guardian’s source item, London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’, Poolbeg Pharma to test the treatment in NHS hospitals and says it is also developing a GLP-1 weight loss pill A London-based startup is about to trial a drug at six NHS hospitals that could stop people on cancer immunotherapy getting a life-threatening side-effect. Poolbeg Pharma said its oral drug POLB 001 could make treatment for blood cancer safer by preventing cytokine release syndrome (CRS) , when the immune system goes into overdrive and attacks the body, leading to organ damage. Continue reading…

Context

The development sits in VINI’s Science file for readers following research, health, climate, space, medicine, and scientific institutions. The original report is linked so readers can check the source account, follow later updates, and compare new coverage against the first published record. The source item is dated 2026-06-14T10:00:41+00:00.

What to watch

Open questions include whether primary sources issue follow-up statements, whether local or market impacts become clearer, and whether additional reporting changes the timeline or adds material context.

Source

Primary source: London startup to trial drug to prevent cancer therapy side-effect ‘cytokine storm’ via The Guardian. VINI cites and links the source; it does not reproduce the publisher’s full article text without rights clearance.

This source-cited VINI report links to the original publisher record. VINI does not republish third-party article bodies without rights clearance. 1 source listed.

Source links

Reader comments

Moderated discussion

Account access

Comments are open to authenticated approved accounts, screened for spam and abuse, and published only after newsroom moderation unless editors change the story control.

Loading comments.